Skip to content

Evotec SE

EVO EVOTF

CIK 0001412558 · Pharmaceutical Preparations · Nasdaq, OTC

  • Evotec AG (until 2021-09-23)
← back to feed
Revenue (TTM)
€796.97M
+2.0% YoY FY Dec 2025
Net Income (TTM)
−€196.08M
−133.7% YoY FY Dec 2025
EPS Diluted (TTM)
−€1.11
−136.2% YoY FY Dec 2025
Gross Margin
14.4%
FY Dec 2025
Operating Margin
-17.9%
FY Dec 2025
Net Margin
-24.6%
FY Dec 2025
Free Cash Flow (TTM)
—
FY Dec 2025
Cash
€306.39M
FY Dec 2025
Total Debt
—
FY Dec 2025
Shares Outstanding
177.78M sh
FY Dec 2025

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings